<p>Bausch + Lomb Co.（纽约证券交易所代码：BLCO - 获取免费报告）的股票在目前覆盖该公司的十二家券商中获得了 “持有” 的平均评级，Marketbeat 报道称。一位分析师给予该股票卖出建议，六位分析师给予持有建议，五位分析师给予买入建议。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价格为 20.00 美元。</p>
<p>获取 <strong>Bausch + Lomb</strong> 警报：</p>
<ul>
<li>Bausch Health：收购提议可能是释放价值的关键</li>
</ul>
<p>几家研究公司最近对 BLCO 进行了评估。富国银行将 Bausch + Lomb 的目标价格从 26.00 美元下调至 24.00 美元，并在 1 月 16 日的研究报告中对该股票给予 “超配” 评级。摩根士丹利将 Bausch + Lomb 的评级从 “超配” 下调至 “持平”，并在 12 月 2 日的报告中设定了 19.00 美元的目标价格。Stifel Nicolaus 在 1 月 29 日的报告中将 Bausch + Lomb 的目标价格从 19.00 美元下调至 18.00 美元，并对该股票给予 “持有” 评级。Needham &amp; Company LLC 在 2 月 20 日的研究报告中重申了对 Bausch + Lomb 股票的 “持有” 评级。最后，加拿大皇家银行在 2 月 20 日的研究报告中将 Bausch + Lomb 的目标价格从 22.00 美元下调至 18.00 美元，并对该股票给予 “跑赢大盘” 评级。</p>
<p><strong>获取我们对 BLCO 的最新分析</strong></p>
<h2>Bausch + Lomb 股票上涨 1.8%</h2>
<ul>
<li>现在是投资这两只近期 IPO 的时机</li>
</ul>
<p>Bausch + Lomb 股票在周五开盘价为 15.76 美元。该公司的 50 日移动平均价格为 16.48 美元，200 日移动平均价格为 18.10 美元。Bausch + Lomb 的 52 周低点为 13.16 美元，52 周高点为 21.69 美元。该公司的市值为 55.6 亿美元，市盈率为-17.32，市盈增长比率为 0.85，贝塔值为 0.49。该公司的速动比率为 1.01，流动比率为 1.60，债务与股本比率为 0.72。</p>
<p>Bausch + Lomb（纽约证券交易所代码：BLCO - 获取免费报告）最近在 2 月 19 日发布了季度财报。该公司报告本季度每股收益为 0.25 美元，超出分析师一致预期的 0.23 美元，超出幅度为 0.02 美元。Bausch + Lomb 的股本回报率为 3.35%，净利润率为-6.62%。该公司本季度的收入为 12.8 亿美元，而一致预期为 12.6 亿美元。在去年同期，该公司每股收益为 0.24 美元。该公司的季度收入同比增长 9.1%。分析师平均预测，Bausch + Lomb 在当前财政年度的每股收益将达到 0.74 美元。</p>
<h2>机构投资者对 Bausch + Lomb 的看法</h2>
<p>对冲基金和其他机构投资者最近调整了对该股票的持有。阿尔伯塔投资管理公司在第四季度将其在 Bausch + Lomb 的持股增加了 36.0%。阿尔伯塔投资管理公司现在拥有 3,008,193 股该公司的股票，价值 54,328,000 美元，在此期间又购买了 796,400 股。Whitebox Advisors LLC 在第四季度将其在 Bausch + Lomb 的持股增加了 16.1%。Whitebox Advisors LLC 现在拥有 1,443,101 股该公司的股票，价值 26,062,000 美元，在上个季度又收购了 199,856 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Bausch + Lomb 的持股增加了 51.5%。Arrowstreet Capital Limited Partnership 现在拥有 1,218,431 股该公司的股票，价值 21,996,000 美元，在此期间又收购了 414,138 股。King Street Capital Management L.P. 在第四季度将其在 Bausch + Lomb 的持股增加了 55.2%。King Street Capital Management L.P. 现在拥有 1,136,321 股该公司的股票，价值 20,522,000 美元，在上个季度又购买了 404,256 股。最后，Price T Rowe Associates Inc. MD 在第四季度购买了 Bausch + Lomb 的新股份，价值约为 14,122,000 美元。目前，11.07% 的股票由机构投资者持有。</p>
<h2>Bausch + Lomb 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bausch + Lomb 公司在美国、波多黎各、中国、法国、日本、德国、英国、加拿大、俄罗斯、西班牙、意大利、墨西哥、波兰、韩国及国际市场上运营，专注于眼健康。它分为三个部门：视力护理、制药和外科。视力护理部门提供覆盖各种佩戴模式的隐形眼镜，包括日抛和经常更换的隐形眼镜；以及包括非处方眼药水、眼部维生素和矿物补充剂在内的隐形眼镜护理产品，旨在解决各种问题，如眼部过敏、结膜炎、干眼和红眼缓解。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过 Bausch + Lomb</li>
<li>CD 计算器：定期存款计算器</li>
<li>关于亚马逊股票的一切信号买入——是时候加仓了吗？</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>五个理由说明 Five Below 的股价今年将上涨</li>
<li>如何投资小盘股</li>
<li>博通：为什么这只芯片股票仍然是长期 AI 投资的首选</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJMQ08?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJMQ08"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bausch + Lomb 吗？</h2>
<p>在你考虑 Bausch + Lomb 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Bausch + Lomb 并不在名单上。</p>
<p>虽然 Bausch + Lomb 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BLCO

<p>Bausch + Lomb 公司（纽约证券交易所代码：BLCO）获得了十二家券商的 “持有” 共识评级。一位分析师将其评级为卖出，六位分析师评级为持有，五位分析师评级为买入。12 个月的平均目标价为 20.00 美元。最近的目标价包括来自富国银行的 24.00 美元、来自摩根士丹利的 19.00 美元，以及来自 Stifel Nicolaus 的 18.00 美元。该股票开盘价为 15.76 美元，市值为 55.6 亿美元，市盈率为-17.32。Bausch + Lomb 报告上个季度每股收益为 0.25 美元，超出预期</p>

<p>Shares of Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) have earned an average rating of &#34;Hold&#34; from the twelve brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $20.00.</p>
<div class="lb-trans"><p>Bausch + Lomb Co.（纽约证券交易所代码：BLCO - 获取免费报告）的股票在目前覆盖该公司的十二家券商中获得了 “持有” 的平均评级，Marketbeat 报道称。一位分析师给予该股票卖出建议，六位分析师给予持有建议，五位分析师给予买入建议。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价格为 20.00 美元。</p>
</div><p>Get <strong>Bausch + Lomb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bausch + Lomb</strong> 警报：</p>
</div><ul>
<li>Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value</li>
</ul>
<div class="lb-trans"><ul>
<li>Bausch Health：收购提议可能是释放价值的关键</li>
</ul>
</div><p>Several research firms recently weighed in on BLCO. Wells Fargo &amp; Company dropped their price objective on shares of Bausch + Lomb from $26.00 to $24.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, January 16th. Morgan Stanley lowered Bausch + Lomb from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $19.00 target price for the company. in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on Bausch + Lomb from $19.00 to $18.00 and set a &#34;hold&#34; rating on the stock in a report on Wednesday, January 29th. Needham &amp; Company LLC restated a &#34;hold&#34; rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Finally, Royal Bank of Canada dropped their target price on Bausch + Lomb from $22.00 to $18.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, February 20th.</p>
<div class="lb-trans"><p>几家研究公司最近对 BLCO 进行了评估。富国银行将 Bausch + Lomb 的目标价格从 26.00 美元下调至 24.00 美元，并在 1 月 16 日的研究报告中对该股票给予 “超配” 评级。摩根士丹利将 Bausch + Lomb 的评级从 “超配” 下调至 “持平”，并在 12 月 2 日的报告中设定了 19.00 美元的目标价格。Stifel Nicolaus 在 1 月 29 日的报告中将 Bausch + Lomb 的目标价格从 19.00 美元下调至 18.00 美元，并对该股票给予 “持有” 评级。Needham &amp; Company LLC 在 2 月 20 日的研究报告中重申了对 Bausch + Lomb 股票的 “持有” 评级。最后，加拿大皇家银行在 2 月 20 日的研究报告中将 Bausch + Lomb 的目标价格从 22.00 美元下调至 18.00 美元，并对该股票给予 “跑赢大盘” 评级。</p>
</div><p><strong>Get Our Latest Analysis on BLCO</strong></p>
<div class="lb-trans"><p><strong>获取我们对 BLCO 的最新分析</strong></p>
</div><h2>Bausch + Lomb Stock Up 1.8 %</h2>
<div class="lb-trans"><h2>Bausch + Lomb 股票上涨 1.8%</h2>
</div><ul>
<li>It’s Time To Nibble On These Two Recent IPOs</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是投资这两只近期 IPO 的时机</li>
</ul>
</div><p>Shares of Bausch + Lomb stock opened at $15.76 on Friday. The business has a 50-day moving average price of $16.48 and a 200 day moving average price of $18.10. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The firm has a market cap of $5.56 billion, a P/E ratio of -17.32, a P/E/G ratio of 0.85 and a beta of 0.49. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72.</p>
<div class="lb-trans"><p>Bausch + Lomb 股票在周五开盘价为 15.76 美元。该公司的 50 日移动平均价格为 16.48 美元，200 日移动平均价格为 18.10 美元。Bausch + Lomb 的 52 周低点为 13.16 美元，52 周高点为 21.69 美元。该公司的市值为 55.6 亿美元，市盈率为-17.32，市盈增长比率为 0.85，贝塔值为 0.49。该公司的速动比率为 1.01，流动比率为 1.60，债务与股本比率为 0.72。</p>
</div><p>Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the business earned $0.24 EPS. The business's quarterly revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bausch + Lomb（纽约证券交易所代码：BLCO - 获取免费报告）最近在 2 月 19 日发布了季度财报。该公司报告本季度每股收益为 0.25 美元，超出分析师一致预期的 0.23 美元，超出幅度为 0.02 美元。Bausch + Lomb 的股本回报率为 3.35%，净利润率为-6.62%。该公司本季度的收入为 12.8 亿美元，而一致预期为 12.6 亿美元。在去年同期，该公司每股收益为 0.24 美元。该公司的季度收入同比增长 9.1%。分析师平均预测，Bausch + Lomb 在当前财政年度的每股收益将达到 0.74 美元。</p>
</div><h2>Institutional Investors Weigh In On Bausch + Lomb</h2>
<div class="lb-trans"><h2>机构投资者对 Bausch + Lomb 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Alberta Investment Management Corp increased its stake in Bausch + Lomb by 36.0% during the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company's stock valued at $54,328,000 after buying an additional 796,400 shares during the period. Whitebox Advisors LLC boosted its holdings in shares of Bausch + Lomb by 16.1% in the fourth quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company's stock valued at $26,062,000 after acquiring an additional 199,856 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after acquiring an additional 414,138 shares during the period. King Street Capital Management L.P. raised its holdings in Bausch + Lomb by 55.2% during the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock worth $20,522,000 after purchasing an additional 404,256 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in Bausch + Lomb during the fourth quarter worth approximately $14,122,000. 11.07% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该股票的持有。阿尔伯塔投资管理公司在第四季度将其在 Bausch + Lomb 的持股增加了 36.0%。阿尔伯塔投资管理公司现在拥有 3,008,193 股该公司的股票，价值 54,328,000 美元，在此期间又购买了 796,400 股。Whitebox Advisors LLC 在第四季度将其在 Bausch + Lomb 的持股增加了 16.1%。Whitebox Advisors LLC 现在拥有 1,443,101 股该公司的股票，价值 26,062,000 美元，在上个季度又收购了 199,856 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Bausch + Lomb 的持股增加了 51.5%。Arrowstreet Capital Limited Partnership 现在拥有 1,218,431 股该公司的股票，价值 21,996,000 美元，在此期间又收购了 414,138 股。King Street Capital Management L.P. 在第四季度将其在 Bausch + Lomb 的持股增加了 55.2%。King Street Capital Management L.P. 现在拥有 1,136,321 股该公司的股票，价值 20,522,000 美元，在上个季度又购买了 404,256 股。最后，Price T Rowe Associates Inc. MD 在第四季度购买了 Bausch + Lomb 的新股份，价值约为 14,122,000 美元。目前，11.07% 的股票由机构投资者持有。</p>
</div><h2>Bausch + Lomb Company Profile</h2>
<div class="lb-trans"><h2>Bausch + Lomb 公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.</p>
<div class="lb-trans"><p>Bausch + Lomb 公司在美国、波多黎各、中国、法国、日本、德国、英国、加拿大、俄罗斯、西班牙、意大利、墨西哥、波兰、韩国及国际市场上运营，专注于眼健康。它分为三个部门：视力护理、制药和外科。视力护理部门提供覆盖各种佩戴模式的隐形眼镜，包括日抛和经常更换的隐形眼镜；以及包括非处方眼药水、眼部维生素和矿物补充剂在内的隐形眼镜护理产品，旨在解决各种问题，如眼部过敏、结膜炎、干眼和红眼缓解。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Bausch + Lomb</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Everything About Amazon Stock Signals a Buy—Time to Load Up?</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>5 Reasons Five Below’s Stock Price Is Heading Higher This Year</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Bausch + Lomb</li>
<li>CD 计算器：定期存款计算器</li>
<li>关于亚马逊股票的一切信号买入——是时候加仓了吗？</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>五个理由说明 Five Below 的股价今年将上涨</li>
<li>如何投资小盘股</li>
<li>博通：为什么这只芯片股票仍然是长期 AI 投资的首选</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJMQ08" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=BLCO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bausch + Lomb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bausch + Lomb 吗？</h2>
</div><p>Before you consider Bausch + Lomb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bausch + Lomb 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Bausch + Lomb 并不在名单上。</p>
</div><p>While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bausch + Lomb 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Rating of "Hold" by Analysts

Market Beat

Bausch + Lomb 公司（纽约证券交易所代码：BLCO）被分析师一致评级为 “持有”